Biocryst Pharmaceuticals Inc.

+0.21 (+1.62%)

Biocryst Says U.S. FDA Approves Its Drug Orladeyo

Published: 12/04/2020 01:54 GMT
Biocryst Pharmaceuticals Inc. (BCRX) - Biocryst Announces FDA Approval of Orladeyo™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients.
Biocryst Pharmaceuticals - Oral, Once-daily Prophylactic Option Enables Hae Patients to Reduce Burden of Therapy.
Biocryst Pharmaceuticals - Orladeyo Approved for Adult and Pediatric Patients 12 Years and Older.
Orladeyo Significantly Reduced Hae Attacks at 24 Weeks.
Hae Attack Reduction Was Sustained Through 48 Weeks.
Orladeyo Was Safe and Well Tolerated.
Biocryst Pharmaceuticals - Reported Adverse Reactions for Orladeyo Were Gastrointestinal Reactions.